Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!

Area of Science:

• Neurology
• Psychiatry
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic neurological disease often causing spasticity.
• Nabiximols (Sativex), an oromucosal spray containing delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), is used to treat MS-related spasticity.
• While generally considered safe for cognition and psychiatric health at standard doses, potential drug interactions exist.

Observation:

• A case study involving a multiple sclerosis patient treated with baclofen and methylprednisolone is presented.
• The patient developed significant behavioral changes, including suicidal ideation, after four weeks of Sativex administration.
• The concurrent use of multiple muscle-relaxant medications complicates the attribution of psychiatric symptoms solely to Sativex.

Findings:

• The study highlights a potential association between Sativex use and emergent neurobehavioral side effects in a predisposed MS patient.
• Concomitant use of muscle relaxants may potentiate neuropsychiatric adverse events.
• The exact contribution of Sativex versus other medications to the observed psychiatric symptoms remains undetermined.

Implications:

• Physicians should exercise increased vigilance when prescribing Sativex and other medications for spasticity in MS patients.
• Awareness of potential neurobehavioral side effects is crucial, particularly in patients with pre-existing vulnerabilities.
• Further research may be warranted to elucidate the specific risks and interactions of Sativex in complex polypharmacy regimens for MS.